Cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands

Journal of the National Cancer Institute

Volumn 101, Issue 15, 2009, Pages 1083-1092

  De Kok, Inge M C M ^a   Van Ballegooijen, Marjolein ^a   Habbema, J Dik F ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

ARTICLE; CANCER INCIDENCE; CANCER MORTALITY; CANCER PREVENTION; CANCER SCREENING; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; NETHERLANDS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROCESS MODEL; QUALITY ADJUSTED LIFE YEAR; UTERINE CERVIX CARCINOMA IN SITU; VACCINATION; ADULT; COST BENEFIT ANALYSIS; ECONOMICS; FEMALE; HUMAN; MIDDLE AGED; UTERINE CERVIX TUMOR; VIROLOGY; VIRUS INFECTION;

ADULT; COST-BENEFIT ANALYSIS; DRUG COSTS; FEMALE; HUMANS; MIDDLE AGED; NETHERLANDS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; QUALITY-ADJUSTED LIFE YEARS; TUMOR VIRUS INFECTIONS; UTERINE CERVICAL NEOPLASMS;

EID: 68249161269     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djp183     Document Type: Article

References (45)

1. Garnett GP, Kim JJ, French K, Goldie SJ. Chapter 21: modelling the impact of HPV vaccines on cervical cancer and screening programmes. Vaccine. 2006;24(suppl 3):S178-S186.
2. Goldie SJ, Kohli M, Grima D, et al. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst. 2004;96(8):604-615.
3. Kulasingam SL, Myers ER. Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. JAMA. 2003;290(6):781-789.
4. Sanders GD, Taira AV. Cost-effectiveness of a potential vaccine for human papillomavirus. Emerg Infect Dis. 2003;9(1):37-48.
5. Taira AV, Neukermans CP, Sanders GD. Evaluating human papillomavirus vaccination programs. Emerg Infect Dis. 2004;10(11):1915-1923.
6. Kim JJ, Goldie SJ. Health and economic implications of HPV vaccination in the United States. N Engl J Med. 2008;359(8):821-832.
7. Rebolj M, van Ballegooijen M, Berkers LM, Habbema D. Monitoring a national cancer prevention program: successful changes in cervical cancer screening in the Netherlands. Int J Cancer. 2007;120(4):806-812.
8. Netherlands Cancer Registry. www.ikcnet.nl/. Mortality figures cervical cancer. 2006. http://www.ikcnet.nl/cijfers/index.php?taal=nl&frequentiemaat= 2®io=Landelijk&soort-kanker=29&soort-morfologie=&periode= 2005&inputRegioLandelijk=on&inputRegioMZ=&uitkomstmaat= 2&periode-input=2005&leeftijdsklassen=l. Accessed April 27, 2009.
9. Karim-Kos HE, de Vries E, Soerjomataram I, Lemmens V, Siesling S, Coebergh JW. Recent trends of cancer in Europe:a combined approach of incidence, survival and mortality for 17 cancer sites since the 1990s. Eur J Cancer. 2008;44(10):1345-1389.
10. Surveillance, Epidemiology, and End Results. Cancer stat fact sheets-cancer of the cervix uteri. 2001-2005. http://seer.cancer.gov/csr/1975- 2005/results-merged/sect-05-cervix-uteri.pdf. Accessed April 27, 2009.
11. van den Akker-van Marie ME, van Ballegooijen M, van Oortmarssen GJ, Boer R, Habbema JD. Cost-effectiveness of cervical cancer screening: comparison of screening policies. J. Natl Cancer Inst 2002;94(3):193-204.
12. Habbema JD, van Oortmarssen GJ, Lubbe JT, van der Maas PJ. The MISCAN simulation program for the evaluation of screening for disease. Comput Methods Programs Biomed. 1985;20(1):79-93.
13. Central Office of Statistics. Mortality by Cause of Death, Age and Sex, Series Al. Voorburg, the Netherlands: CBS; 1994. (In Dutch: CBS, Overledenen Naar Doodsoorzaak, Leeftijd en Geslacht, Serie Al, Voorburg 1950-1992).
14. SIG (Information Centre for Health Care). Hospital Diagnosis Statistics 1963-1985. Utrecht, the Netherlands: Stichting Informatiecentrum voor de Gezondheidszorg; 1985.
15. van Ballegooijen M. Effects and Costs of Cervical Cancer Screening [thesis]. Rotterdam, the Netherlands: Department of Public Health, Erasmus University; 1998.
16. Jacobs MV, Walboomers JM, Snijders PJ, et al. Distribution of 37 mucosotropic HPV types in women with cytologically normal cervical smears: the age-related patterns for high-risk and low-risk types. Int J Cancer. 2000;87(2):221-227.
17. Pecorelli S, Ngan HYS, Hacker NF, eds. Staging Classifications and Clinical Practice Guidelines for Gynaecological Cancers. A collaboration Between FIGO and IGCS. 3rd ed. London, England: FIGO; 2006.
18. van Ballegooijen M, Rebolj M, Essink-Bot ML, Meerding WJ, Berkers LM, Habbema JDF. De effecten en kosten van het bevolkingsonderzoek naar baarmoederhalskanker in Nederland na de herstructurering. Rotterdam, the Netherlands: Erasmus MC, afdeling Maatschappelijke Gezondheidszorg; 2006.
19. van Oortmarssen GJ, Habbema JD. Epidemiological evidence for age-dependent regression of pre-invasive cervical cancer. Br J Cancer. 1991;64(3):559-565.
20. Berkhof J, de Bruijne MC, Zielinski GD, Meijer CJ. Natural history and screening model for high-risk human papillomavirus infection, neoplasia and cervical cancer in the Netherlands. Int J Cancer. 2005;115(2):268-275.
21. Harper DM, Franco EL, Wheeler CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet. 2006;367(9518):1247-1255.
22. Clifford G, Franceschi S, Diaz M, Munoz N, Villa LL. Chapter 3: HPV type-distribution in women with and without cervical neoplastic diseases. Vaccine. 2006;24(suppl 3):S26-S34.
23. Coupe VM, van Ginkel J, de Melker HE, Snijders PJ, Meijer CJ, Berkhof J. HPV16/18 vaccination to prevent cervical cancer in the Netherlands: model-based cost-effectiveness. Int J Cancer. 2009;124(4):970-978.
24. Mandelblatt JS, Lawrence WF, Womack SM, et al. Benefits and costs of using HPV testing to screen for cervical cancer. JAMA. 2002;287(18):2372-2381.
25. Eichler HG, Kong SX, Gerth WC, Mavros P, Jonsson B. Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge? Value Health. 2004;7(5):518-528.
26. Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2002. Cancer incidence, mortality and prevalence worldwide. IARC Cancer Base No. 5 Version 2.0. Lyon, France: IARC Press; 2004.
27. Brisson M, Van de Velde N, De Wals P, Boily MC. The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada. Vaccine. 2007;25(29):5399-5408.
28. Insinga RP, Dasbach EJ, Elbasha EH, Puig A, Reynales-Shigematsu LM. Cost-effectiveness of quadrivalent human papillomavirus (HPV) vaccination in Mexico:a transmission dynamic model-based evaluation. Vaccine. 2007;26(1):128-139.
29. Kulasingam SL, Benard S, Barnabas RV, Largeron N, Myers ER. Adding a quadrivalent human papillomavirus vaccine to the UK cervical cancer screening programme:a cost-effectiveness analysis. Cost Eff Resour Alloc. 2008;6(4).
30. Ginsberg GM, Fisher M, Ben-Shahar I, Bornstein J. Cost-utility analysis of vaccination against HPV in Israel. Vaccine. 2007;25(37-38):6677-6691.
31. Jit M, Vyse A, Borrow R, Pebody R, Soldan K, Miller E. Prevalence of human papillomavirus antibodies in young female subjects in England. Br J Cancer. 2007;97(7):989-991.
32. Ault KA; Future II Study Group. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ:a combined analysis of four randomised clinical trials. Lancet. 2007;369(9576):1861-1868.
33. Leyland E. Human papillomavirus vaccination: stabbing in the dark? Lancet. 2008;372(9639):614.
34. Seeff LC, McKenna MT. Cervical cancer mortality among foreign-born women living in the United States, 1985 to 1996. Cancer Detect Prev. 2003;27(3):203-208.
35. Joura EA, Leodolter S, Hernandez-Avila M, et al. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions:a combined analysis of three randomised clinical trials. Lancet. 2007;369(9574):1693-1702.
36. Chesson HW, Ekwueme DU, Saraiya M, Markowitz LE. Cost-effectiveness of human papillomavirus vaccination in the United States. Emerg Infect Dis. 2008;14(2):244-251.
37. Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007;356(19):1928-1943.
38. van de Laar M, Op de Coul E. Chapter 14: Genital Warts. Bilthoven, the Netherlands: RIVM; 2004.
39. van der Meijden WI, Notowicz A, Blog FB, Langley PC. A retrospective analysis of costs and patterns of treatment for external genital warts in the Netherlands. Clin Ther. 2002;24(1):183-196.
40. Netherlands Cancer Registry. www.ikcnet.nl. Incidence figures cervical cancer. 2003. http://www.ikcnet.nl/cijfers/index.php?taal=nl&frequentiemaat= 1®io=Landelijk&soort-kanker=29&soort-morfologie=&periode= 2003&inputRegioLandelijk=on&inputRegioMZ=&fInvasief= 1&uitkomstmaat=1&periode-input=2003&leeftijdsklassen=1. Accessed June 16, 2009.
41. Villa LL, Costa RL, Petta CA, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women:a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol. 2005;6(5):271-278.
42. Gafni A, Birch S. Incremental cost-effectiveness ratios (ICERs): the silence of the lambda. Soc Sci Med. 2006;62(9):2091-2100.
43. Drummond MF, O'Brien B, Stoddart GL, Torrance GW. Methods for the Economic Evaluation of Health Care Programmes. New York, NY: Oxford University Press; 1997.
44. College voor Zorgverzekeringen. Richtlijnen voor farmaco-economisch onderzoek, geactualiseerde versie. Diemen, the Netherlands: College voor Zorgverzekeringen; 2006.
45. College voor Zorgverzekeringen. Richtlijn voor farmaco-economisch onderzoek. Amstelveen, the Netherlands: College voor Zorgverzekeringen; 1999.